Novartis Gene Therapies
ZOLGENSMA
Manufacturer:
Novartis Gene Therapies
Name:
ZOLGENSMA
HCPCS Code Descriptor:
Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
Category:
J Code
HCPCS:
J3399
NDC(s):
71894-0141-09, 71894-0136-08, 71894-0137-08, 71894-0138-08, 71894-0134-07, 71894-0135-07, 71894-0133-07, 71894-0132-06, 71894-0129-05, 71894-0130-06, 71894-0131-06, 71894-0128-05, 71894-0127-05, 71894-0126-04, 71894-0122-03, 71894-0123-03, 71894-0124-04, 71894-0125-04, 71894-0121-03
Primary Type:
Genetic Disorder
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
ZOLGENSMA is a Genetic Disorder drug manufactured by Novartis Gene Therapies and administered via the Intravenous route of administration. The J Code: J3399 is aligned to the drug ZOLGENSMA.